@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAQ7IBWJIYEA1WGUspWEgtxbgDsQOiag1MtOKI4ONOs6M> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAQ7IBWJIYEA1WGUspWEgtxbgDsQOiag1MtOKI4ONOs6M#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:3708;
    a Protein: .
  
  sub:_2 hasAgent: sub:_3;
    a go:0016301 .
  
  sub:_3 geneProductOf: hgnc:6307;
    a Protein: .
  
  sub:_4 occursIn: mesh:D004730, mesh:D042783, species:9606;
    rdf:object sub:_2;
    rdf:predicate belv:directlyIncreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(HGNC:FIGF) => kin(p(HGNC:KDR))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_6;
    pav:version "1.4" .
  
  sub:_5 prov:value "This redundancy in function will be an important consideration in planning VEGF-specific anti-angiogenic therapies to induce regression of tumour blood vessels.Very little is known about the final step in the angiogenic process, in which vascular sprouts fuse with other sprouts to form loops and circulate the blood into the newly vascularized area (FIG. 2e). Tumours express various pro-angiogenic factors (FIG. 2).Although FGF (fibroblast growth factor) was the first to be discovered,VEGFA is perhaps the most ubiquitous. As well as VEGFA, other VEGF-family members are produced by human tumours, including VEGFC and VEGFD, which both bind to VEGF receptor-2 (VEGFR2) and activate many of the same pathways as VEGFA31.";
    prov:wasQuotedFrom pubmed:12778130 .
  
  sub:_6 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:12778130;
    prov:wasDerivedFrom beldoc:, sub:_5 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:12.974+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}